An Open Label, Phase 1, First-in-human, Study to Evaluate Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of Schlafen12 Complex Inducer (SLFN12 ci) BAY 2666605 in Participants With Metastatic Melanoma and Other Advanced Solid Tumors.
Latest Information Update: 21 Dec 2023
At a glance
- Drugs BAY 2666605 (Primary)
- Indications Carcinoma; Fallopian tube cancer; Glioblastoma; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 08 Dec 2023 Status changed from completed to discontinued.
- 15 May 2023 Status changed from active, no longer recruiting to completed.
- 04 Apr 2023 Planned End Date changed from 14 Mar 2023 to 19 Apr 2023.